数据管理系统

菜单

13:01:34

序号	标题 / 预览内容	原文长度	来源	发布时间入库时间	下载
3215311	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> EU Initiates Deficit Procedure Against Austria: Finance Minister Marterbauer Remains Confident <p> People › Politicians ♦ Published: July 10, 2025; 22:53 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> The European Union has officially initiated an excessive deficit procedure against Austria. This step, based on a recommendation by the European Commission, was decided at a meeting of EU finance ministers in Brussels. The reason for the procedure is that Austria"s budget deficit, at 4.7 percent of GDP last year and a planned 4.5 percent this year, is significantly above the 3 percent limit set in the Maastricht criteria. <p> <a title="Despite the EU deficit procedure that has been initiated, Finance Minister Marterbauer remains optimistic.<small>&copy BKA/Brauneis</small>"><img src="https://www.vindobona.org/images/text/dr-markus-marterbauer-austrian-minister-of-finance-2025-big.jpg" rel="noopener noreferrer">Despite the EU deficit procedure that has been initiated, Finance Minister Marterbauer remains optimistic. / Picture:©BKA/Brauneis <p> <p>Austrian Finance Minister Markus Marterbauer (SPÖ) remained optimistic despite the initiation of proceedings, as reported by "DerStandard" in a video report, emphasizing that all decisions concerning the budget “are made in Austria and not in Brussels.” He does… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> EU Initiates Deficit Procedure Against Austria: Finance Minister Marterbauer Remains Confident - Vindobona.org \| Vienna International News	查看 2382	维也纳通讯社	2025-07-10 00:00:00 2025-07-23 13:01:24	word
3215310	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Austria, Bavaria, and Italy Push for Digital Slot System for Brenner Transit <p> People › Politicians ♦ Published: July 10, 2025; 23:09 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> To alleviate the long-standing congestion on the Brenner transit route, Austria and Bavaria are collaborating with Italy to implement a digital slot system for truck journeys. This initiative was agreed upon by Bavarian Minister-President Markus Söder and Austrian Chancellor Christian Stocker during Söder"s working visit to Vienna. <p> <a title="Austrian Chancellor Christian Stocker (r.) welcomed Markus Söder (l.), Minister-President of the Free State of Bavaria, to a working meeting at the Austrian Federal Chancellery.<small>&copy Bundeskanzleramt (BKA) / Florian Schrötter</small>"><img src="https://www.vindobona.org/images/text/bavarian-minister-president-soder-visits-austrian-chancellor-stocker-2025-big.jpg" rel="noopener noreferrer">Austrian Chancellor Christian Stocker (r.) welcomed Markus Söder (l.), Minister-President of the Free State of Bavaria, to a working meeting at the Austrian Federal Chancellery. / Picture:©Bundeskanzleramt (BKA) / Florian Schrötter <p> <p>This initiative, which was already conceived in 2023 by Bavaria, Tyrol, and South Tyrol, is now to be pushed forward with urgency, even though Italy and Germany have so far been rather reluctant to accept the system. However, Chancellor Stocker emphasized that the approval of all three nation states—Austria, Bavaria, and Italy—is essential for such a traffic management system. He… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Austria, Bavaria, and Italy Push for Digital Slot System for Brenner Transit - Vindobona.org \| Vienna International News	查看 2613	维也纳通讯社	2025-07-10 00:00:00 2025-07-23 13:01:24	word
3215309	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Chinese Embassy Hosts Traditional Summer Festival for China Alumni in Austria <p> More+ › Work & Careers ♦ Published: July 10, 2025; 23:19 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> The Chinese Embassy in Austria hosted its annual summer party for China-Alumni. Around 100 guests from various professional fields attended the event, which celebrated the deep ties and cultural exchange between China and Austria. <p> <a title="The annual summer party hosted by the Chinese Embassy in Austria honors China alumni as key figures in strengthening Chinese-Austrian relations and cultural exchange.<small>&copy Chinese and Austrian crossed flags by Vindobona</small>"><img src="https://www.vindobona.org/images/text/crossed-flags-austria-china-by-vindobona-big.jpg" rel="noopener noreferrer">The annual summer party hosted by the Chinese Embassy in Austria honors China alumni as key figures in strengthening Chinese-Austrian relations and cultural exchange. / Picture:©Chinese and Austrian crossed flags by Vindobona <p> <p>In her speech, Ambassador Qi Mei highlighted the recent positive developments in Chinese-Austrian relations. She particularly praised the contributions made by academic and educational institutions, such as the Department of Chinese Studies at the University of Vienna, to promoting the Chinese language in Austria and intensifying bilateral exchanges.</p><p>The ambassador expressed her… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Chinese Embassy Hosts Traditional Summer Festival for China Alumni in Austria - Vindobona.org \| Vienna International News	查看 2477	维也纳通讯社	2025-07-10 00:00:00 2025-07-23 13:01:24	word
3215308	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Vienna Trilogue on the Future of the Middle East Launched: Vienna Becomes Hub for Peace Efforts <p> People › Diplomats ♦ Published: July 10, 2025; 23:29 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> In a significant diplomatic move, Austrian Foreign Minister Beate Meinl-Reisinger welcomed her counterparts from Germany, Johann Wadephul, and Israel, Gideon Sa"ar, for groundbreaking talks on the future of the Middle East. The meeting, which serves as the kick-off for a now regular “Vienna Trilogue,” focused on urgent efforts to achieve a ceasefire in Gaza, humanitarian aid for the Palestinian civilian population, and Iran"s nuclear program. <p> <a title="Austrian Foreign Minister Beate Meinl-Reisinger (m.) welcomed her counterparts from Israel, Gideon Saar (r.), and Germany, Johann Wadephul (l.), to Vienna.<small>&copy BMEIA Bundesministerium für Europa, Integration und Äußeres / Michael Gruber / Flickr Attribution 2.0 Generic (CC BY 2.0 DEED)</small>"><img src="https://www.vindobona.org/images/text/austrian-foreign-minister-meinl-reisinger-with-her-counterparts-from-germany-and-israel-in-vienna-2025-big.jpg" rel="noopener noreferrer">Austrian Foreign Minister Beate Meinl-Reisinger (m.) welcomed her counterparts from Israel, Gideon Saar (r.), and Germany, Johann Wadephul (l.), to Vienna. / Picture:©BMEIA Bundesministerium für Europa, Integration und Äußeres / Michael Gruber / Flickr Attribution 2.0 Generic (CC BY 2.0 DEED) <p> <p>Austrian Foreign Minister Beate Meinl-Reisinger is currently making strenuous efforts to secure a more prominent role for Austria in Middle East diplomacy, as evidenced in particular by the establishment of the “Vienna Trilogue” with Germany and Israel and <a… <=""></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> </p> <p> <p> <p>Fast News Search</p> </p> <p> <p>Related News</p> <p>Austria"s Meinl-Reisinger Intensifies Middle East Diplomacy and Calls for De-Escalation and Two-State Solution (July 2)</p><p>Austria Strengthens its Commitment to the Reconstruction of Ukraine at the Gymnich Meeting (May 8)</p><p>UN High Commissioner Volker Türk: Israel"s Settlement Construction in the West Bank Condemned as a War Crime (March 18)</p> </p> <p> <p>Read More</p> <p> Vienna Trilogue, Palestine, Palestinian Territories, Johann Wadephul, Nuclear Proliferation, JCPOA Joint Comprehensive Plan of Action, Iran, Israel, IAEA International Atomic Energy Agency, Gideon Sa"ar, Germany, Beate Meinl-Reisinger, Gaza Strip </p> </p> <p> <p>Featured</p> <p>See latest Vindobona Newsletter</p> </p> </p> Vienna Trilogue on the Future of the Middle East Launched: Vienna Becomes Hub for Peace Efforts - Vindobona.org \| Vienna International News	查看 3854	维也纳通讯社	2025-07-10 00:00:00 2025-07-23 13:01:24	word
3215307	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Austria"s Former Top EU General Brieger Urges Massive Increase in Military Preparedness <p> People › Other ♦ Published: July 14, 2025; 10:07 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> After three years at the helm of the European Union"s Military Committee, former Austrian Chief of Staff Robert Brieger returns to Vienna and urges Europe, and Austria in particular, to drastically increase its defense readiness in light of the ongoing threat from Russia. Brieger calls for a paradigm shift—away from the Austrian Armed Forces as a disaster relief force and toward a combat-ready national defense army. A critical examination of Austrian neutrality is “inevitable” in this context. <p> <a title="For three years, Austrian Robert Brieger coordinated EU defense policy in Brussels and urged the EU and Austria to take defense preparedness more seriously.<small>&copy Wikimedia Commons / Chairman of the Joint Chiefs of Staff / CC BY 2.0</small>"><img src="https://www.vindobona.org/images/text/robert-brieger-big.jpg" rel="noopener noreferrer">For three years, Austrian Robert Brieger coordinated EU defense policy in Brussels and urged the EU and Austria to take defense preparedness more seriously. / Picture:©Wikimedia Commons / Chairman of the Joint Chiefs of Staff / CC BY 2.0 <p> <p>General Brieger, who headed the EU Military Committee from May 2022 to May 2025, and now the former Austrian Chief of Staff Robert Brieger is returning to Vienna and sounding the alarm about the latest developments in an interview with the Austria Press Agency (APA), as reported by… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Austria's Former Top EU General Brieger Urges Massive Increase in Military Preparedness - Vindobona.org \| Vienna International News	查看 2636	维也纳通讯社	2025-07-14 00:00:00 2025-07-23 13:01:24	word
3215306	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Human Rights in Austria: NGOs Make 159 Demands on the Government <p> People › Other ♦ Published: July 14, 2025; 17:16 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> According to numerous non-governmental organizations (NGOs), the human rights situation in Austria continues to leave much to be desired. In the run-up to the United Nations" Universal Periodic Review (UPR), more than 300 civil society organizations issued a joint statement addressing an impressive 159 demands to the Austrian government. <p> <as human rights situation, resulting in a joint statement from the UN"s Universal Periodic Review outlining 159 demands.<small>&copy Wikimedia Commons / Thomas Ledl / CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)</small>"><img src="https://www.vindobona.org/images/text/the-headquarters-of-the-austrian-ministry-of-justice-in-the-palais-trautson-big.jpg" rel="noopener noreferrer">NGOs have expressed concerns about Austria"s human rights situation, resulting in a joint statement from the UN"s Universal Periodic Review outlining 159 demands. / Picture:©Wikimedia Commons / Thomas Ledl / CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0) <p> <p>These demands, which were presented at a press conference as reported by ORF, range from the withdrawal of messenger surveillance to a constitutionally enshrined right to housing and measures against violence against women. Florian Horn of the Austrian League for Human Rights emphasized that progress in implementing previous… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Human Rights in Austria: NGOs Make 159 Demands on the Government - Vindobona.org \| Vienna International News	查看 2572	维也纳通讯社	2025-07-14 00:00:00 2025-07-23 13:01:24	word
3215305	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Patrick Lobis Head of the EU Commission Representation in Austria <p> People › Diplomats ♦ Published: July 14, 2025; 17:31 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> The European Commission has, for a while since handed over the management of its representation in Austria to Patrick Lobis. As the official representative of the European Commission in Austria, Lobis reports directly to President Ursula von der Leyen. <p> <a title="Patrick Lobis is Head of the European Commission Representation in Vienna.<small>&copy Wikimedia Commons / Europäisches Parlament [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)]</small>"><img src="https://www.vindobona.org/images/text/haus-der-europaeischen-union-wien-house-of-the-european-union-in-vienna-big.jpg" rel="noopener noreferrer">Patrick Lobis is Head of the European Commission Representation in Vienna. / Picture:©Wikimedia Commons / Europäisches Parlament [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)] <p> <p>Patrick Lobis, a native of South Tyrol with Austrian and Italian citizenship, brings extensive knowledge and experience in the fields of communication, political analysis, and management to his new position. Previously, Lobis was deputy head of the Political and Economic Intelligence Unit in the European Commission"s Directorate-General for Communication.</p><blockquote… <=""></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> </p> <p> <p> <p>Fast News Search</p> </p> <p> <p>Related News</p> <p>Austria"s Former Top EU General Brieger Urges Massive Increase in Military Preparedness (July 14)</p><p>Vienna Trilogue on the Future of the Middle East Launched: Vienna Becomes Hub for Peace Efforts (July 10)</p><p>EU Initiates Deficit Procedure Against Austria: Finance Minister Marterbauer Remains Confident (July 10)</p> </p> <p> <p>Read More</p> <p> Ursula von der Leyen, Patrick Lobis, European Commission Representation in Austria, EU European Union, EC European Commission, Christian Wigand </p> </p> <p> <p>Featured</p> <p>See latest Vindobona Newsletter</p> </p> </p> Patrick Lobis Head of the EU Commission Representation in Austria - Vindobona.org \| Vienna International News	查看 3377	维也纳通讯社	2025-07-14 00:00:00 2025-07-23 13:01:24	word
3215304	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> ICMPD Director General Michael Spindelegger: Europe Ten Years After the Refuge Crisis <p> People › Diplomats ♦ Published: July 14, 2025; 17:52 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> Ten years after the so-called “refugee crisis” of 2015, Europe is taking stock of its migration policy. While enormous progress has been made in addressing the challenges, experts such as Michael Spindelegger, Director General of the International Centre for Migration Policy Development (ICMPD), warn that the region continues to face growing complexities and political tensions. <p> <as migration crisis necessitating bold policies, honest communication, and global cooperation.<small>&copy Vindobona.org</small>"><img src="https://www.vindobona.org/images/text/icmpd-plaque-1010-vienna-big.jpg" rel="noopener noreferrer">Michael Spindelegger, Director General of ICMPD, highlights Europe"s migration crisis necessitating bold policies, honest communication, and global cooperation. / Picture:©Vindobona.org <p> <p>In an in-depth interview on World Refugee Day, Spindelegger emphasized that the events of 2015 were not a sudden phenomenon, but rather the culmination of long-term developments. Similar discussions about an asylum crisis had already taken place in the 1990s, but these were overshadowed by other global events. “In reality, the ‘crisis’ of 2015 had begun long before and was not so… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> ICMPD Director General Michael Spindelegger: Europe Ten Years After the Refuge Crisis - Vindobona.org \| Vienna International News	查看 2451	维也纳通讯社	2025-07-14 00:00:00 2025-07-23 13:01:24	word
3215303	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Austria Strengthens Security Partnerships with the United Kingdom and Germany <p> People › Other ♦ Published: July 15, 2025; 10:20 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> Austria has deepened its bilateral relations with the United Kingdom and Germany in a series of important security policy consultations. The high-level talks focused on current security policy challenges, strategic interests, and strengthening defense cooperation in a changing global environment. <p> <a title="Austria is committed to maintaining its international security partnerships and contributing to broader European efforts to jointly address present and future complex challenges.<small>&copy Bundesheer/Harald MINICH</small>"><img src="https://www.vindobona.org/images/text/austrian-black-hawk-2009-big.jpg" rel="noopener noreferrer">Austria is committed to maintaining its international security partnerships and contributing to broader European efforts to jointly address present and future complex challenges. / Picture:©Bundesheer/Harald MINICH <p> <p>Security policy consultations between Austria and the United Kingdom took place at the British Ministry of Defense in London. The Austrian delegation was led by Secretary General Dr. Arnold Kammel, while Sebastian Carr, Deputy Head of the Department for European-Atlantic Security Policy, led the British side. Experts from the fields of strategy, the Western Balkans, and the British… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Austria Strengthens Security Partnerships with the United Kingdom and Germany - Vindobona.org \| Vienna International News	查看 2491	维也纳通讯社	2025-07-15 00:00:00 2025-07-23 13:01:24	word
3215302	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Vienna Airport Defies Global Challenges with Strong Half-Year Results <p> Lifestyle & Travel › Travel ♦ Published: July 15, 2025; 12:45 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> Vienna International Airport (VIE) experienced solid passenger growth in the first half of 2025, despite a slight decline in June, attributed to the ongoing conflict between Iran and Israel. A total of 14.7 million passengers traveled through Vienna Airport between January and June, representing a 2.4 percent increase compared to the same period last year. <p> <a title="Vienna Airport experienced a slight drop in passenger numbers in June 2025 due to Middle East tensions, but remained resilient with robust freight volume and diversification of flight destinations.<small>&copy Vienna Airport / Flughafen Wien AG / Roman Boensch</small>"><img src="https://www.vindobona.org/images/text/vienna-airport-big.jpg" rel="noopener noreferrer">Vienna Airport experienced a slight drop in passenger numbers in June 2025 due to Middle East tensions, but remained resilient with robust freight volume and diversification of flight destinations. / Picture:©Vienna Airport / Flughafen Wien AG / Roman Boensch <p> <p>In June 2025, passenger numbers at Vienna Airport fell slightly by 0.4 percent to around 3 million passengers. This decline is primarily attributed to geopolitical tensions in the Middle East, which resulted in a significant drop in passenger numbers to this region (-24.5 percent to 55,103 passengers). “However, the figures remain at a high level,” the airport emphasized in its… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Vienna Airport Defies Global Challenges with Strong Half-Year Results - Vindobona.org \| Vienna International News	查看 2637	维也纳通讯社	2025-07-15 00:00:00 2025-07-23 13:01:24	word
3215301	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Myanmar Takes Over Chairmanship of ASEAN Committee in Vienna <p> People › Diplomats ♦ Published: July 15, 2025; 13:05 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> Myanmar has assumed the chairmanship of the ASEAN Committee in Vienna (ACV). Ambassador Min Thein of Myanmar has pledged to continue ongoing initiatives and further strengthen the unity and commitment of the diplomatic missions of the ASEAN countries in Vienna. The handover took place during the 63rd meeting of the committee, which was chaired by Laos" chargé d"affaires in Austria, Viengxay Thammavong. <p> <a title="The ACV consists of the diplomatic missions of the eight ASEAN countries in Vienna: Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Brunei and Cambodia are not represented by their own embassies in Vienna.<small>&copy Wikimedia Commons; Gunawan Kartapranata, CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/deed.en)</small>"><img src="https://www.vindobona.org/images/text/flags-of-asean-nations-2025-big.jpg" rel="noopener noreferrer">The ACV consists of the diplomatic missions of the eight ASEAN countries in Vienna: Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Brunei and Cambodia are not represented by their own embassies in Vienna. / Picture:©Wikimedia Commons; Gunawan Kartapranata, CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/deed.en) <p> <p>The meeting was attended by representatives of all eight ASEAN member states with diplomatic missions in Vienna: Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Brunei and Cambodia are not represented by their own embassies in Vienna. The ACV serves to represent ASEAN"s common position in bilateral and multilateral contexts in Vienna and to raise… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Myanmar Takes Over Chairmanship of ASEAN Committee in Vienna - Vindobona.org \| Vienna International News	查看 2896	维也纳通讯社	2025-07-15 00:00:00 2025-07-23 13:01:24	word
3215300	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> An Ambassador Without a State: Manizha Bakhtari"s Fight for Afghan Women <p> Lifestyle & Travel › More+ ♦ Published: July 15, 2025; 15:43 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> Vienna"s Filmcasino hosted the powerful new documentary "The Last Ambassador," spotlighting Manizha Bakhtari, Afghanistan"s Ambassador to Austria. The film portrays Bakhtari"s extraordinary decision to continue serving the Afghan people despite no longer representing a recognized government, offering a poignant look into her unwavering commitment in the face of her homeland"s collapse under Taliban rule. <p> <a title="Manizha Bakhtari, despite no longer representing a state, represents a nation of women fighting for visibility, education, and recognition, whose bold, moral, and unyielding diplomacy belongs on the world stage.<small>&copy Embassy of Afghanistan in Vienna</small>"><img src="https://www.vindobona.org/images/text/manizha-bakhtari-ambassador-of-the-islamic-republic-of-afghanistan-big.jpg" rel="noopener noreferrer">Manizha Bakhtari, despite no longer representing a state, represents a nation of women fighting for visibility, education, and recognition, whose bold, moral, and unyielding diplomacy belongs on the world stage. / Picture:©Embassy of Afghanistan in Vienna <p> <p>The screening, organized by the Maltese delegation to the Organization for Security and Cooperation in Europe (OSCE) for the International Day of Women in Diplomacy, gathered an influential audience of diplomats, civil society leaders, and human rights advocates, as… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> An Ambassador Without a State: Manizha Bakhtari's Fight for Afghan Women - Vindobona.org \| Vienna International News	查看 2618	维也纳通讯社	2025-07-15 00:00:00 2025-07-23 13:01:24	word
3215299	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Austria"s Debt Relief: A Focus on Billions <p> People › Politicians ♦ Published: July 16, 2025; 10:57 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> Since the turn of the millennium, Austria has waived debts amounting to around €3.4 billion owed to other countries. This information is based on a recent parliamentary response from the Ministry of Finance, which has drawn particular criticism from the Freedom Party of Austria (FPÖ). <p> <a title="According to Finance Minister Marterbauer, Austria is part of international cooperation programs that provide for debt restructuring or debt relief as part of development aid agreements.<small>&copy BKA/Brauneis</small>"><img src="https://www.vindobona.org/images/text/dr-markus-marterbauer-austrian-minister-of-finance-2025-big.jpg" rel="noopener noreferrer">According to Finance Minister Marterbauer, Austria is part of international cooperation programs that provide for debt restructuring or debt relief as part of development aid agreements. / Picture:©BKA/Brauneis <p> <p>The response sent by SPÖ Finance Minister Marterbauer to FPÖ MPs Norbert Nemeth and Hubert Fuchs shows that since 2000, numerous countries have been fully or partially exempted from their obligations to Austria. The total amount of €3.4 billion corresponds to approximately half of the consolidation volume required in the federal budget for the current year.</p><p>The countries… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Austria's Debt Relief: A Focus on Billions - Vindobona.org \| Vienna International News	查看 2468	维也纳通讯社	2025-07-16 00:00:00 2025-07-23 13:01:24	word
3215298	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Ultimatum to Iran: Four Countries set Deadline for Nuclear Agreement by End of August <p> People › Diplomats ♦ Published: July 16, 2025; 11:06 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> Diplomatic efforts to reach a nuclear agreement with Iran are entering a critical phase. The United States and the three European powers, France, Germany, and Great Britain, have set Iran a definitive deadline of the end of August to reach an agreement on its nuclear program. <p> <a title="The US and three European countries have set Iran a deadline for a nuclear agreement.<small>&copy Wikimedia Commons; sipo (https://www.flickr.com/photos/siposoft) / Flickr Attribution 2.0 Generic (CC BY 2.0 DEED, https://creativecommons.org/licenses/by/2.0/deed.en)</small>"><img src="https://www.vindobona.org/images/text/the-building-of-irans-ministry-of-foreign-affairs-2010-big.jpg" rel="noopener noreferrer">The US and three European countries have set Iran a deadline for a nuclear agreement. / Picture:©Wikimedia Commons; sipo (https://www.flickr.com/photos/siposoft) / Flickr Attribution 2.0 Generic (CC BY 2.0 DEED, https://creativecommons.org/licenses/by/2.0/deed.en) <p> <p>This was agreed yesterday in a telephone conversation between U.S. Secretary of State Marco Rubio and his counterparts from the three European countries, as reported by the news website Axios, citing insider sources.</p><p>If no agreement is reached by this deadline, the European… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Ultimatum to Iran: Four Countries set Deadline for Nuclear Agreement by End of August - Vindobona.org \| Vienna International News	查看 2508	维也纳通讯社	2025-07-16 00:00:00 2025-07-23 13:01:24	word
3215297	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Austria Strengthens Senegal as an Anchor of Stability in West Africa <p> People › Politicians ♦ Published: July 17, 2025; 11:19 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> Defense Minister Klaudia Tanner welcomed her Senegalese counterpart, Birame Diop, to Vienna to discuss the critical security situation in the Sahel region, joint peacekeeping missions, and bilateral cooperation. Tanner emphasized Senegal"s central role as a “stable anchor” in West Africa and underscored the need to strengthen Austrian and European engagement in the region. <p> <as coast.<small>&copy Austrian Armed Forces Photograph</small>"><img src="https://www.vindobona.org/images/text/austrian-armed-forces-in-afghanistan-big.jpg" rel="noopener noreferrer">The Austrian Armed Forces are training combat divers to combat drug smuggling and human trafficking off Senegal"s coast. / Picture:©Austrian Armed Forces Photograph <p> <p>The meeting, which was initiated by General Diop and co-financed by Denmark, provided an opportunity for a broader exchange with defense colleagues from various countries on issues of peacekeeping. Senegal has been actively participating in African EU missions and UN operations for years, and also supports Austria"s candidacy for a seat on the UN Security… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Austria Strengthens Senegal as an Anchor of Stability in West Africa - Vindobona.org \| Vienna International News	查看 2331	维也纳通讯社	2025-07-17 00:00:00 2025-07-23 13:01:24	word
3215296	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Andranik Hovhannisyan as Armenian Ambassador to Austria <p> People › Diplomats ♦ Published: July 17, 2025; 13:16 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> His Excellency Andranik Hovhannisyan has been the Ambassador of the Republic of Armenia to the Republic of Austria for some time now. With an impressive career in the Armenian diplomatic service, Hovhannisyan brings a wealth of experience and expertise to his new role. <p> <a title="PR of Armenia to the IAEA, HE Mr. Andranik Hovhannisyan (l.), and IAEA Director General Rafael Mariano Grossi (r.).<small>&copy Flickr / Dean Calma / IAEA [CC BY 2.0 (https://creativecommons.org/licenses/by-sa/2.0/)]</small>"><img src="https://www.vindobona.org/images/text/h-e-andranik-hovhannisyan-ambassador-of-armenia-2025-big.jpg" rel="noopener noreferrer">PR of Armenia to the IAEA, HE Mr. Andranik Hovhannisyan (l.), and IAEA Director General Rafael Mariano Grossi (r.). / Picture:©Flickr / Dean Calma / IAEA [CC BY 2.0 (https://creativecommons.org/licenses/by-sa/2.0/)] <p> <p>Born on April 6, 1976, in Yerevan, Armenia, Ambassador Hovhannisyan has a remarkable academic background. He completed his studies at renowned institutions, including the Fletcher School of Law and Diplomacy in Boston, USA (2000), and Yerevan State University, where he earned his doctorate in history (Ph.D.) (1998-2001). He also deepened his knowledge of Arabic at the Department of… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Andranik Hovhannisyan as Armenian Ambassador to Austria - Vindobona.org \| Vienna International News	查看 2475	维也纳通讯社	2025-07-17 00:00:00 2025-07-23 13:01:24	word
3215295	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Austrian Government Opens Bregenz Festival 2025 with Appeal for Visionary and Responsible "Mindset" <p> More+ › Events ♦ Published: July 21, 2025; 12:07 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> The Bregenz Festival 2025 had been officially opened. The opening ceremony, which attracted high-ranking representatives from politics and culture, focused on Austrian President Alexander Van der Bellen and Austrian Vice-Chancellor Andreas Babler. Both argued in their speeches that we are living in a forward-looking and critical time, emphasizing the importance of showing courage and responsibility. <p> <as rarely performed tragedy “Oedipe,” the new house opera of this year"s festival.<small>&copy Österreichische Präsidentschaftskanzlei / Peter Lechner/HBF</small>"><img src="https://www.vindobona.org/images/text/high-ranking-officials-at-the-bregenz-festival-2025-big.jpg" rel="noopener noreferrer">The opening speeches were followed by the cultural kick-off with George Enescu"s rarely performed tragedy “Oedipe,” the new house opera of this year"s festival. / Picture:©Österreichische Präsidentschaftskanzlei / Peter Lechner/HBF <p> <p>It was inevitable that in Austria, of all places, at the opening of the Bregenz Festival in Freischütz, politicians would try to sound a note of caution in the turbulent times in which we live. In his speech, Austrian President Alexander Van der Bellen described the current world situation as a time of multiple crises – from global pressure on liberal democracy and human rights to… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Austrian Government Opens Bregenz Festival 2025 with Appeal for Visionary and Responsible "Mindset" - Vindobona.org \| Vienna International News	查看 2591	维也纳通讯社	2025-07-21 00:00:00 2025-07-23 13:01:24	word
3215294	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Austria on Course for a Digital and Sustainable Era in Europe <p> People › Politicians ♦ Published: July 21, 2025; 14:53 ♦ (Vindobona) <img src="https://www.vindobona.org/images/cont/icon_premium.gif" rel="noopener noreferrer"> </p> The Austrian federal government has presented a positive mid-year review of its work for the first half of 2025. Chancellor Christian Stocker, Vice-Chancellor Andreas Babler, and Foreign Minister Beate Meinl-Reisinger presented the progress made in implementing the government program and reaffirmed the goal of making Austria future-proof, securing prosperity, strengthening competitiveness, and advocating for a strong Europe, as Chancellor Stocker reiterated during his trips to Italy and France. <p> <a title="Austrian Chancellor Christian Stocker (r.) traveled to Paris for a working visit with French President Emmanuel Macron (l.).<small>&copy Bundeskanzleramt (BKA) / Florian Schrötter</small>"><img src="https://www.vindobona.org/images/text/austrian-chancellor-stocker-in-paris-2025-big.jpg" rel="noopener noreferrer">Austrian Chancellor Christian Stocker (r.) traveled to Paris for a working visit with French President Emmanuel Macron (l.). / Picture:©Bundeskanzleramt (BKA) / Florian Schrötter <p> <p>Chancellor Christian Stocker emphasized that numerous measures had been initiated over the past four months. “We want to deliver on what we promised: to do what is right for Austria,” said Stocker. He stressed the importance of the reform partnership between the federal government, the states, cities, and municipalities as crucial for implementing necessary… </p></p> <p> <p><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story.jpg" rel="noopener noreferrer"><img src="https://www.vindobona.org/images/layout/banner-id25-get-the-full-story-mobile.jpg" rel="noopener noreferrer"></p><p>or Log In</p> </p> <p> <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> </p> Austria on Course for a Digital and Sustainable Era in Europe - Vindobona.org \| Vienna International News	查看 2603	维也纳通讯社	2025-07-21 00:00:00 2025-07-23 13:01:24	word
3215293	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> Global Drug Policy at a Crossroads: Crisis at the United Nations Due to U.S. Policy and Funding Cuts <p> People › Diplomats ♦ Published: Yesterday; 15:12 ♦ (Vindobona) </p> International drug policy and the organization that implements it, the United Nations Office on Drugs and Crime (UNODC), are in the midst of an unprecedented crisis. A dramatic shift in U.S. policy under Donald Trump"s “might makes right” approach, drastic funding cuts, and the unexpected departure of Executive Director Ghada Waly have undermined the United Nations" long-standing consensus-building mechanisms, casting doubt on the future of global drug control. <p> <as resignation exacerbated the crisis at UNODC amid the global crisis of multilateralism.<small>&copy UNODC/Max Brucker / Flickr Attribution (CC BY 2.0, https://creativecommons.org/licenses/by/2.0/)</small>"><img src="https://www.vindobona.org/images/text/unodc-ghada-waly-at-a-conference-on-narcotic-drugs.jpg" rel="noopener noreferrer">Ghada Waly"s resignation exacerbated the crisis at UNODC amid the global crisis of multilateralism. / Picture:©UNODC/Max Brucker / Flickr Attribution (CC BY 2.0, https://creativecommons.org/licenses/by/2.0/) <p> <p>Deep divisions among UN member states have been evident for some time, and the actions of the US, Russia, and China have long reflected the law of the jungle. Under Donald Trump in particular, the US has also developed new and uncomfortable tendencies against multilateralism. The 68th session of the Commission on Narcotic Drugs (CND) in March 2025 also revealed these tensions in Vienna at UNODC. Traditionally, decisions in the CND were made by consensus, the so-called “Vienna Spirit.” But this year, all resolutions, including a landmark resolution from Colombia, were adopted by vote. The US, Russia, and Argentina opposed the resolution introduced by Colombia, which calls for the establishment of a high-level UN body to improve the implementation of global drug policy. This marks a departure from previous practice and reflects increasing geopolitical tensions.</p><p>The United States, once a reliable partner of European countries on drug policy issues, took an unexpectedly confrontational stance at this year"s CND. Its new positions affected not only drug policy, but also the UN agendas for sustainable development, gender, and human rights. This surprised many delegations and led to an unusual confrontation with the European Union and other member states.</p><p>Financial turmoil: Existential threat to the UNODC</p><p>The political changes in Washington have the most direct impact on the financial stability of the UNODC. Historically, the US has been the office"s largest and most active donor, contributing more than a third of its funding prior to the recent cuts. The sudden suspension of US foreign aid has plunged the UNODC, which is heavily dependent on voluntary contributions, into an unprecedented crisis.</p><p>Ghada Waly, the outgoing Executive Director of the UNODC, summed up the precarious situation in her opening speech at the CND: “It is no secret that the UNODC is facing a serious funding problem. [...] We cannot do more with less when the illegal drug market has more available every day [...]. And we cannot achieve the impact you need if we do not have the resources [...].”</p><p>Projects have already been discontinued or will be discontinued shortly, and employees are seeing their contracts expire. Although contributions from the EU and Gulf states have increased, no other donor can compensate for the loss of US support. The organization must prepare itself for the fact that growth has come to an end and that innovative reforms are the only option.</p><p>Leadership vacuum and the need for reform</p><p>The crisis is exacerbated by the unexpected resignation of Ghada Waly in May. This leaves the organization without leadership at one of its most vulnerable moments. Founded in 1997 through the merger of UN drug and crime programs, UNODC has steadily expanded its mandates but has always been vulnerable to the preferences of donor countries due to its project-based funding.</p><p>The international community now faces the challenge of filling the gap left by the US. However, this should not only be done through financial means, but also through a realignment of the organization. The UNODC"s previous, rather cautious and conservative leadership strategy will not suffice in the current situation.</p><p>Joint fight against drug trafficking as a ray of hope</p><p>Despite the deep divisions, there have been some rare moments of cooperation, particularly in the fight against drug trafficking and organized crime, with a focus on synthetic opioids. A resolution introduced by Poland on behalf of the EU on safety in the dismantling of synthetic drug laboratories was adopted. At a side event supported by Mexico, GI-TOC, and Canada, representatives from Mexico, the US, and Canada discussed the common challenges of fentanyl markets in North America. This showed that the need for cooperation on common threats that transcend individual political perspectives remains.</p><p>Uncertain future, but opportunities for progress</p><p>The impact of the break with consensus-based decision-making, the functioning of the new high-level body, and the consequences of US funding cuts are still unclear. But the political space for drug policy has changed dramatically. The adoption of the Colombian resolution shows that progress can be made despite political challenges.</p><p>The UNODC is facing a critical period. The new Convention on Cybercrime will be opened for signature this year, and the UNODC will serve as its secretariat. The 25th anniversary of the United Nations Convention against Transnational Organized Crime (UNTOC) will be celebrated in November 2025, and the next Crime Congress will take place in April 2026.</p><p>The appointment of a new Executive Director will be crucial. The UN needs a leader with ambition, fresh ideas, and political clout to overcome the unprecedented challenges. The international community must now seize common opportunities for progress and cooperation in this state of flux. All channels for international cooperation on drug policy and the fight against organized crime must remain open.</p><p>Global Initiative against Transnational Organized Crime</p><p>UNODC</p> </p> <p> Copyright © Vindobona. You may share using our article tools. Please don"t cut articles from Vindobona and redistribute by email or post to the web. </p> Global Drug Policy at a Crossroads: Crisis at the United Nations Due to U.S. Policy and Funding Cuts - Vindobona.org \| Vienna International News	查看 6948	维也纳通讯社	2025-07-23 13:00:28 2025-07-23 13:01:24	word
3215292	有图 <p> <p> Tweet </p> <p> <p> Share </p> </p> <p> <img src="https://www.vindobona.org/images/cont/email.gif" rel="noopener noreferrer"> </p> </p> North Korea Appoints New Ambassador to Austria <p> People › Diplomats ♦ Published: Yesterday; 15:24 ♦ (Vindobona) </p> North Korea has reportedly named veteran diplomat Kyong Hak Min as its new ambassador to Austria, a move that could see him also represent Pyongyang at international organizations in Vienna. <p> <a title="Austria has long been a significant and comparatively neutral diplomatic outpost for North Korea since the two countries established diplomatic ties in 1974, especially due to the United Nations Offices in Vienna.<small>&copy IAEA International Atomic Energy Agency</small>"><img src="https://www.vindobona.org/images/text/iaea-vic-un-united-nations-vienna-big.jpg" rel="noopener noreferrer">Austria has long been a significant and comparatively neutral diplomatic outpost for North Korea since the two countries established diplomatic ties in 1974, especially due to the United Nations Offices in Vienna. / Picture:©IAEA International Atomic Energy Agency <p> <p>The appointment appears to have been made quietly, as neither North Korea nor Austria has officially announced it, but NK News, which describes itself as a specialist information source focusing on North Korea, has reported on the development. Kyong Hak Min is expected to arrive in Austria shortly to take up his new position. He succeeds the current ambassador, Choe Kang Il. Diplomatic records indicate that a diplomat with the same name already served as embassy counselor at the North Korean embassy in Germany from 2009 to the early 2010s.</p><p>Austria has traditionally been an important and relatively neutral diplomatic outpost for North Korea. Previous ambassadors to Vienna have been high-ranking figures, underscoring the importance Pyongyang attaches to this relationship.</p><p>However, this historical connection has also been exploited to misuse Vienna as a hub for illegal activities, including arms smuggling and espionage operations. In particular, the now-closed Golden Star Bank, which was owned by the sanctioned Taesong Bank and was shut down in 2004 on suspicion of money laundering and financing North Korean weapons, was at the center of these activities. In addition, the Vienna-based International Taekwondo Federation (ITF), an organization founded by South Korean General Choi Hong-Hi, who later defected to North Korea, has been scrutinized by Austrian authorities for alleged links to North Korean financial activities. However, the ITF denies any wrongdoing.</p><p>Relations between North Korea and Austria have been complex and at times ambivalent since they were established in 1974. While Vienna has long been an important diplomatic base for Pyongyang in Europe, especially during the Cold War, the relationship has also been marred by controversies surrounding North Korea"s illegal activities. The appointment of a new ambassador signals North Korea"s continued interest in maintaining a presence in Central Europe, even though the future of bilateral relations remains uncertain amid global developments and North Korea"s controversial nuclear policy.</p> </p> <p> Copyright © Vindobona. You may share using our article tools. Please don"t cut articles from Vindobona and redistribute by email or post to the web. </p> North Korea Appoints New Ambassador to Austria - Vindobona.org \| Vienna International News	查看 3666	维也纳通讯社	2025-07-23 13:00:25 2025-07-23 13:01:24	word
3215291	无图 <p> Jul 08, 2025 </p> <p> <p> <p> <p>Coartem<sup>®</sup> (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic) Novartis plans to introduce infant-friendly Coartem Baby on largely not-for-profit basis to increase access in areas where malaria is endemic <p>Basel, July 8, 2025 – Novartis today announced Coartem<sup>®</sup> (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet<sup>®</sup> Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.</p> <p>Eight African countries also participated in the assessment and are now expected to issue rapid approvals under the Swiss agency’s Marketing Authorization for Global Health Products procedure.<sup>1</sup> Novartis plans to introduce the infant-friendly treatment on a largely not-for-profit basis to increase access in areas where malaria is endemic.</p> <p>“For more than three decades, we have stayed the course in the fight against malaria, working relentlessly to deliver scientific breakthroughs where they are needed most,” said Vas Narasimhan, CEO of Novartis. “Together with our partners, we are proud to have gone further to develop the first clinically proven malaria treatment for newborns and young babies, ensuring even the smallest and most vulnerable can finally receive the care they deserve.”</p> <p>Until now, there has been no approved malaria treatment for infants weighing less than 4.5 kilograms, leaving a treatment gap. They have instead been treated with formulations intended for use in older children, which may increase the risk of overdose and toxicity. Malaria vaccines are also not approved for the youngest babies.<sup>2</sup></p> <p>Some 30 million babies are born in areas of malaria risk in Africa every year,<sup>3</sup> with one large survey across West Africa reporting infections ranging between 3.4% and 18.4% in infants younger than 6 months old.<sup>4 </sup>However, current data on malaria in young babies is extremely limited as they are rarely included in clinical trials of antimalarial agents.<sup>5,6</sup></p> <p>“The available malaria treatments have only been properly tested in children aged at least 6 months because smaller infants are usually excluded from treatment trials,” said Professor Umberto D"Alessandro, Director of the MRC Unit, The Gambia at the London School of Hygiene and Tropical Medicine. “That matters because neonates and young infants have immature liver function and metabolize some medicines differently, so the dose for older children may not be appropriate for small babies.”</p> <p>The new dose strength designed for young infants was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica consortium, which is co-funded by the European & Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency. The treatment is dissolvable, including in breast milk, and has a sweet cherry flavor to make it easier to administer.</p> <p>“Malaria is one of the world’s deadliest diseases, particularly among children. But with the right resources and focus, it can be eliminated,” said Martin Fitchet, CEO of MMV. “The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox.”</p> <p>About the CALINA study</p><p>The Swissmedic approval is based on the Phase II/III CALINA study, which investigated a new ratio and dose of Coartem (artemether-lumefantrine) to account for metabolic differences in babies under 5 kilograms. It is indicated for the treatment of infants and neonates weighing between 2and less than 5kilograms with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum.Coartem is known by the brand name Riamet in Switzerland and some other countries.</p> <p>About malaria</p><p>Malaria is a life-threatening disease caused by a parasite and spread to humans by some types of mosquitoes. According to the most recent WHO data, there were 263 million cases of malaria and 597,000 deaths in 2023, almost all of them in Africa. Children under 5 years old accounted for about three in four malaria deaths in the region.<sup>7</sup></p> <p>About Novartis in malaria innovation</p><p>Novartis finds breakthroughs for diseases neglected by science and brings innovative medicines to communities on the margins of healthcare, building on 85 years of innovation in global health. Novartis has built the industry’s largest pipeline of treatments to control or eliminate malaria and neglected tropical diseases, backed by nearly USD 490 million in funding for global health R&D since 2021. This includes four new antimalarial compounds with the potential to combat rising drug resistance, one of which is just completing Phase III trials, and another which is a potential single-dose cure. Since 1999, Novartis has delivered more than 1.1 billion treatment courses of antimalarials, mostly at no profit, including 500 million treatments of a child-friendly formulation for babies weighing at least 5 kilograms.</p> <p>Disclaimer</p><p>This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.</p> <p>About Novartis </p><p>Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.</p> <p>Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.</p> <p>About MMV</p><p>MMV is a Swiss not-for-profit working to deliver a portfolio of accessible medicines with the power to treat, prevent and eliminate malaria. Born in 1999 to drive health equity, MMV closes critical gaps in research, development and access – to expand the use of existing antimalarials and innovate new compounds. This starts with women and children. As of 2024, MMV-supported products have effectively treated more than 711 million patients.</p> <p>For more information, visit www.mmv.orgFollow MMV on social media: X, LinkedIn, YouTube and Facebook</p> <p>References</p> Eight African countries participated in Swissmedic’s Marketing Authorization for Global Health Products (MAGHP) procedure for Coartem Baby – Burkina Faso, Cote d’Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda -- and are expected to approve the medicine following approval by Swissmedic. These eight countries account for 47% of estimated cases in 2023, according to the WHO’s Global Health ObservatoryWHO. Malaria vaccines (RTS,S and R21)Reddy, Valentina et al. Global estimates of the number of pregnancies at risk of malaria from 2007 to 2020: a demographic study. The Lancet Global Health, Volume 11, Issue 1, e40 - e47Ceesay SJ et al. Malaria Prevalence among Young Infants in Different Transmission Settings, Africa. Emerg Infect Dis. 2015 Jul;21(7):1114-21. doi: 10.3201/eid2107.142036. PMID: 26079062; PMCID: PMC4480393.D’Alessandro U, et al. Malaria in infants aged less than six months - is it an area of unmet medical need? Malar J. 2012 Dec 2;11:400. doi: 10.1186/1475-2875-11-400. PMID: 23198986; PMCID: PMC3529680.Dobbs, et al. Plasmodium malaria and antimalarial antibodies in the first year of life.Parasitology. 2016;143(2):129-138. doi:10.1017/S0031182015001626WHO. Malaria. <p># # #</p> Novartis Media Relations</p><p>E-mail: [emailprotected]</p><p>Novartis Investor Relations</p><p>Central investor relations line: +41 61 324 7944</p><p>E-mail: [emailprotected] </p> </p> </p> </p> <p> </p> Novartis receives approval for first malaria medicine for newborn babies and young infants \| Novartis	查看 10981	诺华	2025-07-08 00:00:00 2025-07-23 12:49:31	word
3215290	无图 <p> Jul 17, 2025 </p> <p> <p> <p> <p>Ad hoc announcement pursuant to Art. 53 LR</p>Q2 net sales grew +11% (cc<sup>1</sup>, +12% USD) with core operating income<sup>1</sup> up +21% (cc, +20% USD) Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc)Core operating income margin<sup>1</sup> reached 42.2%, +340 basis points (cc), mainly driven by higher net salesQ2 operating income grew +25% (cc, +21% USD); net income up +26% (cc, +24% USD)Q2 core EPS<sup>1</sup> grew +24% (cc, +23% USD) to USD 2.42Q2 free cash flow<sup>1</sup> of USD 6.3 billion (+37% USD) driven by higher net cash flows from operating activitiesH1 net sales up +13% (cc, +12% USD) and core operating income up +24% (cc, +21% USD)Q2 selected innovation milestones:Pluvicto Phase III PSMAddition study positive readout in PSMA+ mHSPCVanrafia (atrasentan) FDA accelerated approval for IgANOAV101 IT US and EU submissions for SMAVotoplam Phase II PIVOT-HD study positive readout in Huntington’s diseaseRemibrutinib Phase II study positive readout in food allergyInitiating up-to USD 10 billion share buyback to be completed by year-end 2027Full-year 2025 guidance<sup>2</sup> raised for core operating incomeSales expected to grow high single digit (unchanged)Core operating income expected to grow low teens (from low double-digit)<p>1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 40 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance assumptions on page7.</p><p>Basel, July 17, 2025 – Commenting on Q2 2025 results, Vas Narasimhan, CEO of Novartis, said:</p><p>“Novartis delivered another strong quarter, with double-digit sales and core operating income growth. We continue to drive strong performance on our ongoing launches for Kisqali, Pluvicto, and Scemblix, demonstrating the replacement power in our portfolio. We also delivered important pipeline milestones including a third positive Phase III readout for Pluvicto in hormone-sensitive prostate cancer and global filings for OAV101 IT in SMA. Our robust balance sheet and confidence in our mid and long-term growth enable us to initiate an up-to USD 10 billion share buyback as part of our commitment to balanced capital allocation."</p>Key figuresQ2 2025Q2 2024% changeH1 2025H1 2024 % changeUSD m USD mUSDccUSD m USD mUSDccNet sales14 05412 512121127 28724 3411213Operating income4 8644 01421259 5277 3872933Net income4 0243 24624267 6335 9342931EPS (USD)2.071.6029323.912.913437Free cash flow6 3334 615379 7246 65346Core operating income5 9254 953202111 5009 4902124Core net income4 7104 00818199 1927 6892022Core EPS (USD)2.421.9723244.693.772427StrategyOur focus<p>Novartis is a “pure-play” innovative medicines company. We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale. Geographically, we are focused on growing in our priority geographies – the US, China, Germany and Japan.</p>Our prioritiesAccelerate growth: Renewed attention to deliver high-value medicines (NMEs) and focus on launch excellence, with a rich pipeline across our core therapeutic areas.Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with substantial cash generation and a strong capital structure supporting continued flexibility.Strengthen foundations: Unleashing the power of our people, scaling data science and technology and continuing to build trust with society.FinancialsSecond quarter<p>Net sales were USD 14.1 billion (+12%, +11% cc), with volume contributing 12 percentage points to growth. Generic competition had a negative impact of 2 percentage points, pricing had a positive impact of 1 percentage point, and currency had a positive impact of 1 percentage point.</p><p>Operating income was USD 4.9 billion (+21%, +25% cc), mainly driven by higher net sales, partly offset by higher investments behind priority brands and launches and net expense from legal matters.</p><p>Net income was USD 4.0 billion (+24%, +26% cc), mainly driven by higher operating income, partly offset by higher net financial expense. EPS was USD 2.07 (+29%, +32% cc), benefiting from the lower weighted average number of shares outstanding.</p><p>Core operating income was USD 5.9 billion (+20%, +21% cc), mainly driven by higher net sales, partly offset by higher investments behind priority brands and launches. Core operating income margin was 42.2% of net sales, increasing 2.6 percentage points (3.4 percentage points cc).</p><p>Core net income was USD 4.7 billion (+18%, +19% cc), mainly due to higher core operating income, partly offset by higher income taxes and net financial expense. Core EPS was USD 2.42 (+23%, +24% cc), benefiting from the lower weighted average number of shares outstanding.</p><p>Free cash flow amounted to USD 6.3 billion (+37% USD), compared with USD 4.6 billion in the prior-year quarter, driven by higher net cash flows from operating activities.</p>First half<p>Net sales were USD 27.3 billion (+12%, +13% cc), with volume contributing 14 percentage points to growth. Generic competition had a negative impact of 2 percentage points, pricing had a positive impact of 1 percentage point, benefiting from revenue deduction adjustments mainly in the US, and currency had a negative impact of 1 percentage point.</p><p>Operating income was USD 9.5 billion (+29%, +33% cc), mainly driven by higher net sales and contingent consideration adjustments, partly offset by higher investments behind priority brands and launches.</p><p>Net income was USD 7.6 billion (+29%, +31% cc), mainly driven by higher operating income, partly offset by higher income taxes and net financial expense. EPS was USD 3.91 (+34%, +37% cc), benefiting from the lower weighted average number of shares outstanding.</p><p>Core operating income was USD 11.5 billion (+21%, +24% cc), mainly driven by higher net sales, partly offset by higher investments behind priority brands and launches. Core operating income margin was 42.1% of net sales, increasing 3.1 percentage points (3.7 percentage points cc).</p><p>Core net income was USD 9.2 billion (+20%, +22% cc), mainly due to higher core operating income, partly offset by higher income taxes and net financial expense. Core EPS was USD 4.69 (+24%, +27% cc), benefiting from the lower weighted average number of shares outstanding.</p><p>Free cash flow amounted to USD 9.7 billion (+46% USD), compared with USD 6.7 billion in the prior-year period, driven by higher net cash flows from operating activities.</p>Q2 priority brands<p>Underpinning our financial results in the quarter is a continued focus on key growth drivers (ranked in order of contribution to Q2 growth) including:</p>Kisqali(USD 1 177 million, +64% cc) sales grew strongly across all regions, including +100% growth in the US with strong momentum from the recently launched early breast cancer indication as well as continued share gains in metastatic breast cancerEntresto(USD 2 357 million, +22% cc) sustained robust, demand-led growth globallyKesimpta(USD 1 077 million, +33% cc) sales grew across all regions driven by increased demand and strong accessScemblix(USD 298 million, +79% cc) sales grew across all regions, demonstrating the continued high unmet need in CML and continued strong momentum from the recently launched early-line indication in the USLeqvio(USD 298 million, +61% cc) continued steady growth, with a focus on increasing account and patient adoption, and continuing medical educationPluvicto(USD 454 million, +30% cc) showed encouraging demand uptake in the US following the pre-taxane metastatic castration-resistant prostate cancer (mCRPC) approval, as well as continued access expansion ex-US in the post-taxane mCRPC settingCosentyx(USD 1 629 million, +6% cc) sales grew mainly in the US and Europe, driven by recent launches as well as volume growth in core indicationsFabhalta(USD 120 million) sales grew driven by continued launch execution across all markets in PNH as well as recent launches in IgAN and C3G in the USLutathera(USD 207 million, +17% cc) sales grew mainly in the US, Europe and Japan due to increased demand and earlier-line adoption, particularly in the US and JapanZolgensma(USD 297 million, -17% cc) sales declined reflecting a lower incidence of SMA compared to prior year, while demand remained robustNet sales of the top 20 brands in the second quarter and first halfQ2 2025% changeH1 2025 % changeUSD mUSDccUSD mUSDccEntresto2 35724224 6182222Cosentyx1 629763 1631111Kisqali1 17764642 1335960Kesimpta1 07735331 9763838Tafinlar + Mekinist5731071 1251313Promacta/Revolade502-8-91 048-2-1Jakavi5241181 01678Xolair44342899910Ilaris47730278962424Pluvicto45432308252626Tasigna327-27-27704-16-15Zolgensma297-15-17624-3-3Sandostatin Group303-3-3620-7-6Leqvio29864615556766Scemblix29882795367978Lutathera20718174001616Exforge Group1917737003Lucentis173-37-39362-39-38Diovan Group154-4-430413Galvus Group123-18-17247-17-14Top 20 brands total11 584161422 4211617R&D update - key developments from the second quarterNew approvalsVanrafia</p><p>(atrasentan)FDA granted accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy.Coartem</p><p>(artemether and lumefantrine)In July, Swissmedic approved Coartem Baby, the first clinically proven malaria treatment specifically designed for newborns and infants between 2-5 kg. This milestone paves the way for registration in eight African countries through the Marketing Authorization for Global Health Products (MAGHP) procedure.Regulatory updatesOAV101 IT (onasemnogene abeparvovec)Regulatory submissions for OAV101 IT in patients with spinal muscular atrophy (SMA) were completed in the US and EU.Results from ongoing trials and other highlightsPluvicto</p><p>(lutetium Lu177 vipivotide tetraxetan)At a prespecified interim analysis, the Phase III PSMAddition trial in PSMA+ metastatic hormone-sensitive prostate cancer(mHSPC) met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) in patients treated with Pluvicto plus standard of care (SoC)versus SoC alone. The study also showed a positive trend in overall survival in favor of the Pluvicto arm. Data will be presented at an upcoming medical meeting and, based on FDA feedback, submitted for regulatory review in H2 2025.Cosentyx</p><p>(secukinumab)In the Phase III GCAptAIN study, Cosentyx did not demonstrate a statistically significant improvement in sustained remission compared to placebo in adults with newly diagnosed or relapsing giant cell arteritis (GCA). Safety in GCA was consistent with the known safety profile of Cosentyx.Kisqali</p><p>(ribociclib)A new subgroup analysis of the Phase III NATALEE trial in HR+/HER2- early breast cancer (eBC) showed that patients receiving Kisqali plus endocrine therapy continued to see consistent reductions in risk of recurrence across all efficacy measures, regardless of age and menopausal status, at median follow-up of 44.2 months. Data presented at ASCO.Fabhalta</p><p>(iptacopan)In the Phase IIIb APPULSE-PNH study, adult PNH patients with hemoglobin (Hb) levels ≥10g/dL who switched to Fabhalta from anti-C5 therapies experienced clinically meaningful improvements in Hb levels. The vast majority (92.7%) achieved Hb ≥12g/dL, reaching normal or near-normal levels. No patients treated with Fabhalta required transfusions, experienced breakthrough hemolysis or had any major adverse vascular events during the treatment period. Data presented at EHA.Scemblix </p>(asciminib)In the Phase IIIb ASC4START trial evaluating the tolerability and efficacy of Scemblix versusnilotinib in adult patients with newly diagnosed Ph+ CML-CP, patients treated with Scemblix had a55% lower risk of discontinuation due to AEs vs nilotinib, and 12.7% more patients treated with Scemblixachieved majormolecular responsesby week 12 vs those treated with nilotinib.Data presented at ASCO and EHA.VotoplamThe Phase II PIVOT-HD study of votoplam in patients with Stage 2 and Stage 3 Huntington"s disease met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels at Week 12 (p<0.0001), with durable, dose-dependent lowering observed through Month 12. Across all dose levels and disease stages, votoplam showed a favorable safety and tolerability profile, with no treatment-related serious adverse events or neurofilament light chain protein (NfL) spikes. Together with our partner, PTC Therapeutics, we are evaluating the results and plan to engage with the HD community and regulatory authorities to inform next steps.RemibrutinibA Phase II study with remibrutinib in food allergy met its primary endpoint with a statistically significant and clinically meaningful benefit. These data support remibrutinib"s potential as a first-in-class oral BTK inhibitor that reduces the risk of severe allergic reactions, including anaphylaxis. Phase III study planning is underway.IanalumabNovartis will not advance investigation of ianalumab in hidradenitis suppurativa following a Phase II proof-of-concept study which did not meet our target criteria despite demonstrating efficacy vs placebo. No new safety signals were observed and all other studies for ianalumab in B-cell driven diseases continue as planned.Rapcabtagene autoleucel </p>(YTB323)A Phase I/II study of rapcabtagene autoleucel, a rapidly manufactured CD19 CAR-T therapy using the T-Charge platform, demonstrated the expansion of CAR-T cells, deep B cell depletion, early and sustained improvement in overall disease activity, and a favorable benefit/risk profile in 21 patients with severe refractory SLE up to 12 months after treatment. Data presented at EULAR.ZigakibartUpdated results from the Phase I/II study for zigakibart in IgAN showed a robust and clinically meaningful reduction in proteinuria of 60.4% from baseline and eGFR stabilization over 100 weeks of treatment. To date, this is the longest duration of treatment reported for an anti-APRIL agent, demonstrating long-term safety and efficacy. Data presented at ERA. The Phase III BEYOND trial is ongoing with anticipated readout in 2026.Selected transactionsNovartis has completed the acquisition of Regulus Therapeutics, a clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus’ lead asset, farabursen, is a potential first-in-class oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) that recently completed Phase Ib. The acquisition is aligned with the therapeutic area focus of Novartis and leverages its strength and expertise in renal disease. </p><p> In July, Novartis entered into an agreement with Sironax, granting Novartis an exclusive option to acquire its Brain Delivery Module (BDM) platform, a differentiated blood-brain-barrier crossing technology designed to enhance the brain delivery of therapeutics of various modalities.Capital structure and net debt<p>Retaining a good balance between investment in the business, a strong capital structure, and attractive shareholder returns remains a priority.</p><p>During the first half of 2025, Novartis repurchased a total of 48.8 million shares for USD 5.3 billion on the SIX Swiss Exchange second trading line under the USD 15 billion share buyback (announced in July 2023 and completed on July 1, 2025, with a total of 140.9 million shares repurchased over this period). In addition, 1.6 million shares (equity value of USD 0.2 billion) were repurchased from employees. In the same period, 11.2 million shares (equity value of USD 0.6 billion) were delivered to employees related to equity-based compensation plans. Novartis aims to offset the dilutive impact from equity-based compensation plans of employees over the remainder of the year. Consequently, the total number of shares outstanding decreased by 39.2 million versus December 31, 2024. These treasury share transactions resulted in an equity decrease of USD 4.9 billion and a net cash outflow of USD 5.4 billion.</p><p>Net debt increased to USD 23.8 billion at June 30, 2025, compared to USD 16.1 billion at December 31, 2024. The increase was mainly due to the free cash flow of USD 9.7 billion being more than offset by the USD 7.8 billion annual dividend payment, cash outflows for treasury share transactions of USD 5.4 billion and net cash outflow for M&A, intangible assets transactions and other acquisitions of USD 3.1 billion.</p><p>As of Q2 2025, the long-term credit rating for the company is Aa3 with Moody’s Ratings and AA- with S&P Global Ratings.</p>2025 outlook </p><p> Barring unforeseen events; growth vs. prior year in ccNet salesExpected to grow high single-digitCore operating incomeExpected to grow low-teens<p>Key assumption: </p>We continue to assume Entresto US generic entry in mid-2025 for forecasting purposes, though timing of generic entry is subject to ongoing IP and regulatory litigationForeign exchange impact <p>If mid-July exchange rates prevail for the remainder of 2025, the foreign exchange impact for the year would be positive 1 percentage point on net sales and negative 1 percentage point on core operating income. The estimated impact of exchange rates on our results is provided monthly on our website.</p>Key figures<sup>1</sup>Q2 2025Q2 2024% changeH1 2025H1 2024% changeUSD m USD mUSDccUSD m USD mUSDccNet sales14 05412 512121127 28724 3411213Operating income4 8644 01421259 5277 3872933As a % of sales34.632.134.930.3Net income4 0243 24624267 6335 9342931EPS (USD)2.071.6029323.912.913437Net cash flows from </p><p>operating activities6 6644 8753710 3097 14044Non-IFRS measuresFree cash flow6 3334 615379 7246 65346Core operating income5 9254 953202111 5009 4902124As a % of sales42.239.642.139.0Core net income4 7104 00818199 1927 6892022Core EPS (USD)2.421.9723244.693.772427<p>1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 40 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.</p><p>Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below:</p><p>https://ml-eu.globenewswire.com/resource/download/1403b1dc-887b-4bec-8b02-080540c4ebf4/</p>Disclaimer<p>This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “anticipate,” “can,” “will,” “continue,” “ongoing,” “growth,” “launch,” “expect,” “expand,” “deliver,” “accelerate,” “guidance,” “outlook,” “priority,” “potential,” “momentum,” “commitment,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding results of ongoing clinical trials; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings; or by discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or regarding our capital structure. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits or synergies from the transactions described in this press release will be achieved in the expected timeframe, or at all. In particular, our expectations could be affected by, among other things: uncertainties concerning global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding the success of key products, commercial priorities and strategy; uncertainties in the research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; uncertainties regarding our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; uncertainties in the development or adoption of potentially transformational digital technologies, including artificial intelligence, and business models; uncertainties surrounding the implementation of our new IT projects and systems; uncertainties regarding potential significant breaches of information security or disruptions of our information technology systems; uncertainties regarding actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requirements; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.</p><p>All product names appearing in italics are trademarks owned by or licensed to Novartis.</p>About Novartis<p>Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.</p><p>Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X and Instagram.</p><p>Novartis will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Novartis website. A replay will be available after the live webcast by visiting https://www.novartis.com/investors/event-calendar.</p><p>Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below. Additional information is provided on our business and pipeline of selected compounds in late-stage development. A copy of today"s earnings call presentation can be found at https://www.novartis.com/investors/event-calendar.</p>Important datesOctober 28, 2025Third quarter & nine months 2025 resultsNovember 19-20, 2025Meet Novartis Management 2025 (London, UK)December 1, 2025Social Impact & Sustainability annual investor event (virtual)February 4, 2026Fourth quarter & full year 2025 results<p># # #</p>Novartis Media Relations</p><p>E-mail: [emailprotected]</p>Novartis Investor Relations</p><p>Central investor relations line: +41 61 324 7944</p><p>E-mail: [emailprotected]</p><p>Please find full media release in English attached and on the following link:</p><p>Media release (PDF)</p><p>Further language versions are available through the following links:</p><p>German version is available through the following link:</p><p>Medienmitteilung (PDF)</p> </p> </p> </p> <p> </p> Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance \| Novartis	查看 25911	诺华	2025-07-17 00:00:00 2025-07-23 12:49:31	word
3215289	无图 <p> Jul 17, 2025 </p> <p> <p> <p> <p>Ad hoc announcement pursuant to Art. 53 LR</p> Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive Committee (ECN)After an extraordinary 22-year career at Novartis and more than 12 years as a member of the ECN, Harry Kirsch will retire and step down from the ECN on March 15, 2026 <p>Basel, July 17, 2025 – Novartis announced today the appointment of Mukul Mehta as the Chief Financial Officer (CFO) and a member of the Executive Committee of Novartis (ECN), effective March 16, 2026. Mukul succeeds Harry Kirsch, who has served as CFO since 2013, and will retire from Novartis after an extraordinary 22-year career with the company. Harry will continue in his role as CFO and member of the ECN until March 15, 2026.</p> <p>“It has been a tremendous privilege to serve Novartis for the past 22 years. I am proud of the transformation we’ve led - from streamlining the company from six divisions to three, to the successful spinoffs of Alcon and Sandoz, and the divestitures of our stakes in the consumer healthcare joint venture with GSK and in Roche. Together, we’ve built a truly focused medicines company. I leave with deep gratitude for the teams I’ve worked with and have full confidence in Mukul’s leadership,” said Harry Kirsch, CFO of Novartis.</p> <p>Mukul brings over 20 years of experience at Novartis, having held key finance leadership roles across geographies and business units. He brings deep expertise in the pharmaceutical industry and an in-depth understanding of Novartis. Mukul was recently appointed to the role of Head of BPA, Digital Finance and Tax, where he will continue until March of next year. His career includes serving as CFO International for three years, ad-interim President International, CFO Pharmaceuticals business unit, CFO Novartis Business Services, CFO Pharmaceuticals Europe business, and Country CFO of France, Poland, and Norway. Known for his operational excellence, commercial acumen, and people-first leadership style, Mukul has consistently driven performance through data-driven decision-making and inclusive team engagement.</p> <p>“I am honored to take on the role of CFO at Novartis,” said Mukul Mehta. “I’ve had the privilege of growing with this company and working alongside exceptional colleagues. I look forward to continuing our journey as a focused medicines company and delivering sustainable value for patients and shareholders.”</p> <p>Vas Narasimhan, CEO of Novartis said, “Harry’s impact on Novartis has been profound. He played a pivotal role in driving what has so far been one of our strongest periods of growth and strategic transformation. Under Harry’s leadership, the company’s financial performance has significantly improved as evidenced by our strong balance sheet, improved core operating income margin, and robust free cash flow. I thank him for his unwavering commitment and wish him the very best in his next chapter. I am also looking forward to welcoming Mukul to the ECN. His deep knowledge of our business, strong financial expertise, and collaborative style position him well to guide our financial strategy and finance organization through our next phase of growth.”</p> <p>Mukul holds a degree in Management from the Jamnalal Bajaj Institute of Management Studies in India and an MBA from INSEAD France.</p> <p>Disclaimer</p> <p>This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “confidence,” “continuing,” “commitment” or similar terms, or by express or implied discussions regarding the goals, effects and consequences of the CFO leadership transition, or regarding discussions of our strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. In particular, our expectations and assumptions related to this leadership transition could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.</p> <p>About Novartis </p><p>Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.</p> <p>Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.</p> <p># # #</p> Novartis Media Relations</p><p>E-mail: [emailprotected]</p> Novartis Investor Relations</p><p>Central investor relations line: +41 61 324 7944</p><p>E-mail: [emailprotected]</p> </p> </p> </p> </p> <p> </p> Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company \| Novartis	查看 6796	诺华	2025-07-17 00:00:00 2025-07-23 12:49:31	word
3215288	有图 <p> KPL Lao Minister of Foreign Affairs Thongsavanh Phomvihane held bilateral talks with his Russian counterpart Sergey Lavrov on July 10, 2025, in Kuala Lumpur, Malaysia, on the sidelines of the 58th ASEAN Foreign Ministers’ Meeting (AMM), taking place from July 7–11. </p> <p><img src="https://kpl.gov.la/Media/Upload/News/Thumb/2025/07/11/AS%20Russia.jpg" rel="noopener noreferrer"></p><p>(KPL) Lao Minister of Foreign Affairs Thongsavanh Phomvihane held bilateral talks with his Russian counterpart Sergey Lavrov on July 10, 2025, in Kuala Lumpur, Malaysia, on the sidelines of the 58th ASEAN Foreign Ministers’ Meeting (AMM), taking place from July 7–11.</p><p>The two ministers highly valued their meeting, noting it reflects a tradition of bilateral consultations between Laos and Russia during regional and international events. They emphasized that such exchanges significantly contribute to strengthening the longstanding friendship and enhancing cooperation based on the strategic partnership between the Lao PDR and the Russian Federation.</p><p>During the meeting, both sides reviewed the progress of bilateral and multilateral cooperation and reaffirmed their commitment to further expanding collaboration in various areas. These include economy and trade, investment, energy, labour, education, defence, legal affairs, culture, and tourism.</p><p>They also expressed mutual interest in exploring new opportunities for cooperation that could bring shared benefits to both nations.</p><p>On multilateral cooperation, the two ministers appreciated the continued exchange of views and mutual support in international arenas and emphasized the importance of maintaining close coordination.</p><p>They further praised the positive development of ASEAN-Russia cooperation over the years and expressed readiness to work together to deepen the partnership within the ASEAN framework.</p> KPL Lao, Russian Foreign Ministers Hold Bilateral Talks on Sidelines of ASEAN Meeting	查看 2236	老挝新闻通讯社	2025-07-11 08:00:00 2025-07-23 12:48:41	word
3215287	有图 <p> KPL On the sidelines of the 58th ASEAN Foreign Ministers" Meeting, the 32nd ASEAN Regional Forum, and related ministerial gatherings held from July 8–11, 2025, in Kuala Lumpur, Mr. Thongsavanh Phomvihane, Minister of Foreign Affairs of the Lao PDR, met with Mr. Hakan Fidan, Minister of Foreign Affairs of the Republic of Turkiye, to discuss ways to enhance bilateral cooperation. </p> <p><img src="https://kpl.gov.la/Media/Upload/News/Thumb/2025/07/17/Turky.jpg" rel="noopener noreferrer"></p><p>(KPL) On the sidelines of the 58th ASEAN Foreign Ministers" Meeting, the 32nd ASEAN Regional Forum, and related ministerial gatherings held from July 8–11, 2025, in Kuala Lumpur, Mr. Thongsavanh Phomvihane, Minister of Foreign Affairs of the Lao PDR, met with Mr. Hakan Fidan, Minister of Foreign Affairs of the Republic of Turkiye, to discuss ways to enhance bilateral cooperation.</p><p>Both sides expressed satisfaction with the meeting and reaffirmed their commitment to strengthening the long-standing friendly relations and cooperation between Laos and Turkiye. The ministers marked the occasion as a meaningful contribution to deepening the relationship that has grown steadily since the two countries established diplomatic ties on June 26, 1958—now celebrating their 67th anniversary.</p><p>The ministers highlighted the regular exchange of visits by high-level delegations, continued collaboration, and mutual support in regional and international forums as key indicators of the positive momentum in bilateral relations.</p><p>The meeting also focused on future cooperation, with both sides agreeing to:</p><p>Promote further exchange of visits at all levels</p><p>Expand cooperation in trade, investment, agriculture, health, education, labor, and social welfare</p><p>Foster institutional partnerships between women’s unions, youth organizations, and other people-to-people platforms</p><p>Additionally, the two foreign ministers exchanged views on regional and global issues of mutual interest and explored possibilities for deeper engagement within multilateral frameworks.</p><p>The meeting reflects both countries’ shared interest in expanding meaningful cooperation and mutual support on the global stage.</p> KPL Laos and Turkiye Strengthen Bilateral Ties at ASEAN Ministerial Meetings	查看 2571	老挝新闻通讯社	2025-07-17 08:00:00 2025-07-23 12:48:41	word

8225 1 329 Next»